Teva Pharmaceuticals (NYSE: TEVA) released its full-year 2013 forecast, which missed top-line estimates by 4% and bottom-line estimates by 11%. The markets haven't taken the news too badly, opening down 3% but rallying back during the day to a slight gain. In this video, Motley Fool health care analyst David Williamson tells us where these low figures may have come from and what Teva may have in store for 2013.

Brenton Flynn has no positions in the stocks mentioned above. David Williamson owns shares of Amarin plc (ADR). Follow him on Twitter @MotleyDavid. 

The Motley Fool owns shares of Momenta Pharmaceuticals. Motley Fool newsletter services recommend Biogen Idec and Momenta Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.